INS and diabetes mellitus: Current pharmacologic treatment options for children and adolescents with diabetes are limited to insulin, metformin, and two glucagon-like peptide-1 (GLP-1) receptor agonists, i.e., daily liraglutide and once-weekly exenatide extended release (ElSayed et al., 2023).